| Literature DB >> 30183478 |
Fajun Qu1, Jianqing Ye1, Xiuwu Pan1, Junkai Wang2, Sishun Gan1, Chuanmin Chu1, Jian Chu3, Xiangmin Zhang3, Mei Liu1, Hua He4, Xingang Cui1,3.
Abstract
Recent advances in immunotherapy are raising hope to treat clear cell renal cell carcinoma (ccRCC) with PD-L1 inhibitors, but only a small portion of patients are PD-L1 positive. The heterogeneous expression pattern of PD-L1 in patient population suggests that PD-L1 expression is under the control of diverse regulatory mechanisms. Although recent studies have identified numerous novel PD-L1 regulators, reports on microRNAs which modulate PD-L1 expression are much scarce. In this study, we confirmed that PD-L1 expression was up-regulated in ccRCC compared to paired normal tissues. Using miRDB and miRTarBase, 11 microRNAs were predicted to target PD-L1. After measuring the microRNA panel with TaqMan assays, we found that microRNA-497-5p down-regulation was associated with PD-L1 up-regulation. In TCGA-KIRC dataset, microRNA-497-5p down-regulation was also associated with PD-L1 up-regulation as well as shorter survival. We further validated that PD-L1 was a direct target of microRNA-497-5p in two RCC cell lines. In addition, microRNA-497-5p inhibited cell proliferation, clone formation and migration, while promoted apoptosis in in-vitro assays. Our study reveals a novel regulatory mechanism of PD-L1 expression and the potential of miR-497-5p as therapeutic target and biomarker deserves further investigation.Entities:
Keywords: Clear cell renal cell carcinoma; PD-L1; immune checkpoint pathway; immunotherapy; microRNA-497-5p
Mesh:
Substances:
Year: 2018 PMID: 30183478 DOI: 10.1080/1061186X.2018.1479755
Source DB: PubMed Journal: J Drug Target ISSN: 1026-7158 Impact factor: 5.121